<p>This submission includes genomic data derived from the study of clinical samples from two different phase II trials. These trials evaluated the clinical efficacy and safety of avelumab or M7824 in the treatment of adults with recurrent respiratory papillomatosis (RRP). Subjects with aggressive RRP were treated with three to six doses of avelumab or M7824. Pre-treatment or post-treatment snap frozen papilloma and normal mucosa samples were subjected to whole exome sequencing and bulk RNA-seq. A total of twenty subjects were enrolled and treated. </p>

Avelumab or M7824 for People with Recurrent Respiratory Papillomatosis

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis